|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0002199,
umls-concept:C0010802,
umls-concept:C0023473,
umls-concept:C0031525,
umls-concept:C0038952,
umls-concept:C0184511,
umls-concept:C0205197,
umls-concept:C0231174,
umls-concept:C0443252,
umls-concept:C0814225,
umls-concept:C0871261,
umls-concept:C0939537,
umls-concept:C1521828,
umls-concept:C1521991,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C2911692
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2004-9-20
|
|
pubmed:abstractText |
We reviewed 261 patients with chronicphase chronic myelogenous leukemia (CML) after interferon-alpha (IFN-alpha) failure treated with imatinib mesylate 400 mg daily. With a median follow-up time of 45 months, the major cytogenetic response rate was 73% and the complete cytogenetic response rate 63%. The estimated 4-year survival rate was 86%. Multivariate analysis for survival identified hematologic resistance to IFN-alpha (P =.01), splenomegaly (P =.03), and lack of any cytogenetic response after 3 months of therapy (P =.01) to have independent poor prognostic significance. Patients could be divided into good (no adverse factors), intermediate (1 adverse factor), and poor-risk groups (2 or 3 adverse factors; 12% of patients) with estimated 4-year survival rates of 96%, 86%, and 49%, respectively (P <.00001). The 4-year cumulative major molecular response (quantitative reverse transcriptase-polymerase chain reaction [Q-PCR] = BCR-ABL/ABL less than 0.05%) rate was 43% and complete molecular response rate (BCR-ABL undetectable) 26%. Compared with a historical group of 251 similar patients treated with nonimatinib therapies, imatinib mesylate was associated with a better 4-year survival rate (86% versus 43%; P <.0001); the survival advantage was confirmed by multivariate analysis (hazard ratio, 0.19; P <.0001).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0006-4971
|
|
pubmed:author |
pubmed-author:CortesJorge EJE,
pubmed-author:FaderlStefanS,
pubmed-author:Garcia-ManeroGuillermoG,
pubmed-author:GilesFrancisF,
pubmed-author:JonesDanD,
pubmed-author:KantarjianHagop MHM,
pubmed-author:LuthraRajyalakshmiR,
pubmed-author:O'BrienSusanS,
pubmed-author:RiosMary BethMB,
pubmed-author:ShanJianqinJ,
pubmed-author:TalpazMosheM,
pubmed-author:ThomasDeborahD,
pubmed-author:VerstovsekSrdanS
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
104
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1979-88
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:15198956-Aged,
pubmed-meshheading:15198956-Antineoplastic Agents,
pubmed-meshheading:15198956-Disease Progression,
pubmed-meshheading:15198956-Disease-Free Survival,
pubmed-meshheading:15198956-Drug Resistance, Neoplasm,
pubmed-meshheading:15198956-Female,
pubmed-meshheading:15198956-Follow-Up Studies,
pubmed-meshheading:15198956-Fusion Proteins, bcr-abl,
pubmed-meshheading:15198956-Humans,
pubmed-meshheading:15198956-Interferon-alpha,
pubmed-meshheading:15198956-Leukemia, Myelogenous, Chronic, BCR-ABL Positive,
pubmed-meshheading:15198956-Male,
pubmed-meshheading:15198956-Middle Aged,
pubmed-meshheading:15198956-Multivariate Analysis,
pubmed-meshheading:15198956-Philadelphia Chromosome,
pubmed-meshheading:15198956-Piperazines,
pubmed-meshheading:15198956-Proportional Hazards Models,
pubmed-meshheading:15198956-Pyrimidines,
pubmed-meshheading:15198956-Reverse Transcriptase Polymerase Chain Reaction,
pubmed-meshheading:15198956-Time Factors,
pubmed-meshheading:15198956-Treatment Outcome
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha.
|
|
pubmed:affiliation |
Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston 77030, USA. hkantarj@mdanderson.org
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
